PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
238.00 - 242.07
140.53 - 242.25
26.77M / 38.44M (Avg.)
25.64 | 9.39
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
14.21%
Revenue growth under 50% of META's 29.77%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
12.91%
Gross profit growth under 50% of META's 32.69%. Michael Burry would be concerned about a severe competitive disadvantage.
14.27%
EBIT growth below 50% of META's 75.46%. Michael Burry would suspect deeper competitive or cost structure issues.
14.27%
Operating income growth under 50% of META's 75.46%. Michael Burry would be concerned about deeper cost or sales issues.
23.72%
Net income growth under 50% of META's 74.41%. Michael Burry would suspect the firm is falling well behind a key competitor.
24.14%
EPS growth under 50% of META's 71.88%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
20.69%
Diluted EPS growth under 50% of META's 74.19%. Michael Burry would worry about an eroding competitive position or excessive dilution.
0.22%
Share reduction more than 1.5x META's 0.63%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
0.39%
Diluted share count expanding well above META's 0.52%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
6.79%
OCF growth under 50% of META's 28.97%. Michael Burry might suspect questionable revenue recognition or rising costs.
18.74%
FCF growth under 50% of META's 51.20%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
791.77%
10Y revenue/share CAGR above 1.5x META's 342.70%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
135.19%
5Y revenue/share CAGR under 50% of META's 342.70%. Michael Burry would suspect a significant competitive gap or product weakness.
54.63%
3Y revenue/share CAGR under 50% of META's 242.23%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
681.74%
10Y OCF/share CAGR above 1.5x META's 375.17%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
69.32%
Below 50% of META's 375.17%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
31.63%
3Y OCF/share CAGR under 50% of META's 285.51%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
961.26%
Net income/share CAGR above 1.5x META's 341.10% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
80.17%
Below 50% of META's 341.10%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
63.43%
Below 50% of META's 3256.17%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
925.07%
10Y equity/share CAGR 1.25-1.5x META's 673.71%. Bruce Berkowitz would see if strong ROE or conservative payout policy fosters faster book value growth.
142.18%
Below 50% of META's 673.71%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
60.75%
Below 50% of META's 249.33%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.73%
AR growth is negative/stable vs. META's 27.31%, indicating tighter credit discipline. David Dodd confirms it doesn't hamper actual sales.
-77.80%
Inventory is declining while META stands at 0.00%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
2.20%
Asset growth well under 50% of META's 6.32%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
3.29%
50-75% of META's 6.08%. Martin Whitman suspects weaker earnings or capital allocation vs. the competitor.
-0.21%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
8.67%
R&D growth drastically higher vs. META's 3.38%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
14.89%
SG&A growth well above META's 8.75%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.